In a report released today, James Quigley from Goldman Sachs maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a ...

The US overweight and obese population will rise significantly in the next quarter century if current trends continue, and ...

The United Kingdom will study whether the use of weight loss drugs could get people back to work. UK Health Minister Wes ...

Time spent sedentary beyond six hours per day during growth from childhood through young adulthood may cause an excess increase of 4 mmHg in systolic blood pressure, a new study shows.

YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3– TransCon CNP ...

Novo Nordisk (NVO) reportedly plans to phase out production of its human insulin pens while it ramps up production of other ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Are you a print subscriber? Activate your account. By Garett Sloane - 3 min 8 sec ago By Ewan Larkin - 8 min 31 sec ago By ...

Novo Nordisk is working on a new obesity drug that could help patients shed more than any other weight-loss drug on the ...